Disease details

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00480181 (ClinicalTrials.gov)	June 2007	28/5/2007	Efficacy and Safety Evaluation of Nabilone as Adjunctive Therapy to Gabapentin for the Management of Neuropathic Pain in Multiple Sclerosis	A Comparative, Single Center, Randomized, Double-blinded, Parallel, Placebo-controlled Study to Evaluate the Efficacy of Nabilone (Cesamet) as Adjunctive Therapy to Gabapentin (Neurontin) in the Management of Neuropathic Pain (NPP) Symptoms in Subjects With Multiple Sclerosis (MS)	Neuropathic Pain;Multiple Sclerosis	Drug: nabilone;Other: placebo	University of Manitoba	Valeant Pharmaceuticals International, Inc.	Completed	18 Years	65 Years	Both	50	Phase 4	Canada
2	NCT00381264 (ClinicalTrials.gov)	September 2006	25/9/2006	Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Multiple Sclerosis	A Multicenter Trial Evaluating the Efficacy of Cesamet™ for the Symptomatic Treatment of Pain in Patients With Multiple Sclerosis	Multiple Sclerosis	Drug: Cesamet™ (nabilone)	NEMA Research, Inc.	NULL	Completed	18 Years	75 Years	Both	23	Phase 4	United States